Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Editas Medicine, Inc.NASDAQ: EDIT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $483K fell 74.8% year over year, behind the -34.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 65.2% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.
Context
- Depreciation & amortization amounted to 13.0% of revenue in FY2025, down 5.0 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -74.8% toward the trailing-twelve-month pace of -34.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.28M USD
- Year-over-year change
- -9.2%
- 4-year CAGR
- +1.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.28M | -9.2% |
| FY2024 | 2024-12-31 | 5.81M | -4.2% |
| FY2023 | 2023-12-31 | 6.06M | -4.3% |
| FY2022 | 2022-12-31 | 6.34M | +25.4% |
| FY2021 | 2021-12-31 | 5.05M | — |
Depreciation & Amortization vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's LTM Mar 2026 depreciation & amortization of $4.17M is the 6th largest of the 9 companies compared; the peer median is $7.85M.
- Its year-over-year change of -34.0% is the lowest of 9, against a peer median of -1.8%.
- Depreciation & amortization amounts to 10.8% of revenue for EDIT, versus a peer median of 21.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.24M | +1.2% | +16.4% | 14.3% | |
| LTM Sep 2026 | $18.5M | -0.9% | -6.9% | 73.5% | |
| LTM Mar 2026 | $10.18M | +0.4% | +20.7% | — | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $5.7M | -10.2% | +34.3% | 141.4% | |
| LTM Mar 2026 | $4.17M | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| LTM Mar 2026 | $475K | +28.7% | +0.3% | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding EDIT) | $7.85M | -1.8% | +5.5% | 21.5% | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 43.4M | 29.29M | 19.8M | 21.42M | 10M |
| Change in Working Capital | (21.41M) | 8.18M | (1.59M) | 3.45M | (31.23M) |
| Accounts Receivables | 5.78M | (4.88M) | (5.04M) | (6.08M) | 1.09M |
| Inventory | (3.35M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.14M) | 4.37M | (1.49M) | (2.29M) | (2.89M) |
| Other Working Capital | (22.71M) | 8.69M | 4.94M | 11.82M | (29.43M) |
| Other Non-Cash Items | 1.66M | (724K) | (3.23M) | (3.87M) | 10.77M |
| Operating Cash Flow | (163.8M) | (177.35M) | (132.18M) | (210.28M) | (165.24M) |
| Capital Expenditures | (7.98M) | (4.12M) | (4.72M) | (8.83M) | (607K) |
| Acquisitions (Net) | 46.49M | 18K | 0 | 0 | 269K |
| Purchases of Investments | (408.89M) | (315.19M) | (258.52M) | (86.22M) | 0 |
| Sales of Investments | 362.4M | 433.35M | 259.51M | 257.19M | 139.01M |
| Other Investing Activities | (46.49M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.47M) | 114.07M | (3.73M) | 162.15M | 138.67M |
| Debt Repayment | 0 | 0 | 0 | 0 | (2.87M) |
| Common Stock Issued | 249.46M | 1.28M | 117.08M | 56.03M | 43.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.65M | 0 | 960K | 0 | 0 |
| Financing Cash Flow | 282.11M | 1.28M | 118.04M | 56.03M | 40.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 63.84M | (62M) | (17.87M) | 7.89M | 13.9M |
| Free Cash Flow | (171.78M) | (181.47M) | (136.9M) | (219.11M) | (165.85M) |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.